Drug Profile
Research programme: FAAH inhibitors - Advinus Therapeutics
Alternative Names: Fatty acid amide hydrolase inhibitors - AdvinusLatest Information Update: 29 Aug 2023
Price :
$50
*
At a glance
- Originator Advinus Therapeutics
- Class Analgesics
- Mechanism of Action Fatty acid amide hydrolase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Neuropathic pain
Highest Development Phases
- Discontinued Neuropathic pain
Most Recent Events
- 29 Aug 2023 Discontinued - Preclinical for Neuropathic pain in India (unspecified route) (Advinus Therapeutics website, August 2023)
- 28 Feb 2020 No recent reports of development identified for preclinical development in Neuropathic-pain in India
- 21 Jan 2016 FAAH inhibitors - Advinus Therapeutics is available for licensing as of 21 Jan 2016. www.advinus.com